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Introduction: Busulfan (BU) and etoposide (VP) have been
employed as preparative therapy for autologous stem cell
transplantation (autoSCT) in adults with acute myeloid leu-
kemia (AML) for over 20 years. Toxicity and safety signiﬁ-
cantly improved with the transition from oral to intravenous
(IV) BU and the use of pharmacokinetic (PK)-based dosing. In
an attempt to enhance outcomes following autoSCT, we
designed a Phase I study with the following objectives: 1) to
determine the maximum tolerated dose (MTD) of targeted,
dose-escalated IV BU in combination with VP- 60mg/kg and
2) to achieve BU levels within +/- 10% of goal in >80% of
patients (pts) after dose-adjustment (DA).
Methods: Patients with AML in CR1 meeting all eligibility
criteria including, ECOG 0-1, age 18-69, good organ function,
and adequate stem cells stored (>3 x 10e6 CD34 following
consolidation chemotherapy (HDAC+VP)) were prospectively
enrolled. Three cohorts (targeted AUC 1250, 1400 and 1550
mMol*minwere plannedwith Cohort 1 (C1) receiving IV BU at
0.9mg/kg, Cohort 2 (C2) at 1 mg/kg and Cohort 3 (C3) at BU
1.1mg/kg. PK studies were performed after doses 1 (day -10),
4, and 12, with DA occurring with doses 2 and 11 of 16 total
doses. VP was given IV on day -3 with autoSCT on day 0.
Palifermin and standard antimicrobial prophylaxis were used.
Results: To date, 12 pts have undergone autoSCT with tar-
geted, dose-escalated IV BU. Median age 50 (range 24-61).
Cytogenetics were diploid in 5 (1 FLT3+, 2 FLT3 WT, 2 FLT3
unknown). The remaining 7 pts had t(9;11) (2), +21 (2),
t(8;21), 9q-, and 1 failed. TRM was 0% and engraftment
robust; mean ANC >500/uL and platelets >20,000/uL was 11
(range 10-13) and 30 days (range 13-124), respectively.
All pts received a DA after dose #1 and 7 (58.3%) prior to
dose #11. Themean ﬁnal AUCwas 1243 (range 1151-1361) for
C1 and 1464 (range 1401-1558) for C2. All pts in C1 were
within 10% of the target AUC in C1 (range -2.8 to +8.2%)
versus 83% in C2 (range +0.1 to +10.1%). PK studies revealed
BU accumulation at dose 12, with the ﬁnal AUC exceeding
goal by a mean of 14.9% (range 1-35%). Grade 3-4 mucositis
occurred in 50% in C1 and in 66% in C2. Grade 3 hepatic
dysfunction was observed in 33% in C1 and in none in C2.
As of October 2013, 50% of pts are alive and relapse-free.
Median relapse-free survival (RFS) for the entire study group
is 12.6 months (range 2.2-28.9). In C1, RFS is 33% (median13.1
months; range 3.0-28.9) vs. 66% in C2 (median 12.2 months;
range 2.2-20.6). Non-relapse mortality (NRM) was 0% at 100
days post-autoSCT.
Conclusions: Targeted, dose-escalated IV BU in combination
with VP as preparative therapy for autoSCT in AML is safe,
with mucositis being the most signiﬁcant toxicity, limiting
escalation to C3. An AUC target of 1400 was deemed the
maximum acceptable dose. Serum BU levels accumulate,
with higher-than-expected ﬁnal AUC despite interval DA
based on PK studies. Increased BU AUC target is associated
with improved RFS at one year.148
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Background: Although autologous stem cell transplant
(ASCT) can be curative for patients (pts) with relapsed/re-
fractory Hodgkin lymphoma (HL), those with high-risk dis-
ease have long-term progression-free survival (PFS) of
approximately 25% and could beneﬁt from novel thera-
peutic approaches (Majhail 2006). Brentuximab vedotin
(ADCETRIS) comprises an anti-CD30 antibody conjugated
by a protease-cleavable linker to a microtubule-disrupting
agent, monomethyl auristatin E (MMAE). In a pivotal phase 2
study in pts with relapsed or refractory HL following ASCT,
the objective response rate was 75%, with complete re-
missions (CR) in 33% of pts. A phase 3 study was initiated to
evaluate the potential of brentuximab vedotin to prevent
relapse post-ASCT in pts at high risk of lymphoma progres-
sion (ClinicalTrials.gov #NCT01100502).
Methods: The AETHERA trial is a phase 3, randomized,
double-blind, placebo-controlled, multicenter study. After
ASCT, pts received brentuximab vedotin 1.8 mg/kg q3wk and
best supportive care (BSC) or placebo and BSC for up to 16
cycles (approximately 12 months). The primary endpoint is
PFS per independent review; additional endpoints include
overall survival and safety/tolerability. A planned interim
safety and futility analysis was performed in Q4 2012; at that
time 1214/1251 (97%) of the expected CT scans had been
received for central independent review.
Patient Characteristics/Results: Protocol enrollment
occurred from April 2010 through September 2012. A total of
329 pts were enrolled and randomized; of these, 327
received study treatment. Of the 327 pts, 133 (40%) were
enrolled from the United States, 48 (15%) from Western
Europe, and 146 (45%) from Central/Eastern Europe and
Russia. The median age was 32 years (range 18e76) and
52.6% were male. Pts were enrolled in 1 of 3 high-risk cate-
gories: refractory to frontline therapy: 195 pts (59.6%),
relapse <12 months after frontline therapy: 107 pts (32.7%),
and relapse 12 months after frontline therapy with extra-
nodal disease: 25 pts (7.6%). Response to salvage pre-ASCT
was CR: 122 pts (37.3%), PR: 112 pts (34.3%), and SD: 93 pts
(28.4%). Overall, 33% of pts were known to be PET-negative
prior to ASCT. ASCT conditioning regimens were carmustine,
etoposide, cytarabine, and melphalan (BEAM; 61%), cyclo-
phosphamide, carmustine, and etoposide (CBV; 11%), or
other (28%) and included radiation in 6% of pts. All pts were
off treatment as of August 2013. The median number of
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received 16 cycles. A total of 61 pts (19%) discontinued
treatment due to adverse events. Thirty-ﬁve pts (11%) are
known to have died; 31 deaths occurred after disease pro-
gression. One death occurred within 30 days of last dose and
was considered disease-related.
Conclusions: Based upon a planned interim safety and fu-
tility analysis, the IDMC recommended that the AETHERA
trial continue per protocol.149
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High Dose melphalan (200 mg/m2, Mel200) is the standard
conditioning for autologous stem-cell transplant (ASCT) in
multiple myeloma (MM) patients. Forty percent of MM pa-
tients experience some degree of renal insufﬁciency.
Although common practice, there is no standard for dose
reduction in melphalan due to renal impairment. In addition,
there is no clear correlation between melphalan pharmaco-
kinetics in renal failure and outcome in these patients. Here
we report the impact of renal impairment on response and
toxicity outcomes in patients receiving Mel200 as part of
ASCT.
We identiﬁed 111 patients who received Mel200 and ASCT
between 2001 and 2012 at the University of Illinois. Overall,
the majority of patients were African American (60%). Pa-
tients were stratiﬁed by renal function (n¼35 CrCl <60 ml/
min and n¼76 CrCl  60 ml/min). Baseline characteristics
were equal between the 2 groups aside from age (63.2 years
 8.8 vs. 56.8  8.8. P¼.0004). Patients with renal failure
experienced a signiﬁcantly longer time to engraftment
(12.2 days  3.51 vs. 10.6 days  1.7, P¼.0025) and duration
of diarrhea (6.6 days  6.3 vs. 4 days  3.7. P¼.007). Length
of hospital stay was similar between the two groups (17.6
days  4.5 vs. 16.25 days  5.2. P¼.21). Patients with renal
failure spent an average of 10.6 days on total parenteral
nutrition, compared to 7.27 days in patients with normal
renal function (P¼ns). There were no deaths related to
transplant related mortality in either group. . There was no
difference in response rates between the 2 groups in
terms of complete response (50% in CrCl<60ml/min vs. 40%
in Cr Cl > 60ml/min,P¼ns) or overall response rate at day
+90 (75% in CrCl<60ml/min vs. 100% in Cr Cl > 60ml/
min,P¼ns).
This data demonstrates an increase in drug-related toxicities
of diarrhea, and time on TPN in patients with renal impair-
ment conditioned with HD Mel. We hypothesize that this is
due to reduced renal drug clearance. In addition, longer time
to engraftment in the renal failure group may be a result of
greater overall melphalan exposure. In light of the large
numbers of patients impacted by this data, we suggest that
this would be an ideal patient group for the development of
pharmacokinetic based strategies for individual patient
dosing.150
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Background: Pneumocystis jirovecii pneumonia (PJP) is a
potentially life-threatening disease in immunocompromised
patients. The at-risk population includes patients with HIV
infection and low CD4 counts, hematological malignancies,
hematopoietic stem cell (HSC) and solid organ transplant
recipients, and patients receiving glucocorticoids or other
immunomodulatory agents. The highest-risk group of
immunocompromised patients tends to be those with HIV
(human immunodeﬁciency virus) infection, where PJ follows
an indolent course. However, in non-HIV immunocompro-
mised patients, such as HSC transplant recipients, the
infection tends to present with respiratory failure. The inci-
dence of PJP in autologous BMT (bone marrow transplant)
has not been clearly determined, and the indication for
prophylaxis in this setting remains unclear. In this study we
evaluate the incidence of PJP over a 10-year period in re-
cipients of autologous transplants.
Methods: A retrospective analysis of 1191 consecutive
autologous HSC transplants (1-75 years) performed between
1/1/2000 and 6/30/2011 at the University of Michigan BMT
Program. The data was obtained from BMT Program Data-
base at The University of Michigan Comprehensive Cancer
Center. The diagnosis of PJP was established by bronchoscopy
with brochoaveolar lavage (BAL) with polymerase chain re-
action (PCR). We analyzed the following risk factors for the
development of PJP: diabetes, glucocorticoids, infections,
cutaneous T-cell lymphoma, hypertension, and seizure
disorder.
Results: A total number of 5 PJ infections were diagnosed
during study period, resulting in a cumulative incidence of
0.42% (95%CI [0.136449%–0.976969%]) over 10 year period.
All cases occurred between 2001 and 2006, and 3 months or
later following transplantation. Most patients (n¼4) were
older than 50 years old, and all of them were on steroids.
Diagnoses included non-Hodgkin’s lymphoma (n¼3),
Hodgkin’s lymphoma (n¼1) and multiple myeloma (n¼1).
Conditioning regimen was BEAM (BCNU, etoposide, cytar-
abine, melphalan, n¼4) and high dose melphalan (n¼1).
Only 2/5 patients were neutropenic at the time of the
pneumonia, and this did not correlate with the CD34+ cell
infused, which was 2.2x10E6/kg for all patients. Four pa-
tients were on corticosteroids for relapsed lymphoma (n¼2),
ITP (n¼1), BCNU pneumonitis (n¼1). The remainder patient
was on ﬂorinef and was coinfected with candida and herpes
virus. There were no particular comorbidities associated
with the diagnosis of PJ pneumonia. One patient died of PJ,
the remainder were treated successfully.
Conclusions: Our retrospective analysis of a large cohort of
autologous transplant recipients reveals an extremely low
